Subscribe
Webinars
White Papers
Buyer's Guide
PhotonicsNXT
Get Published!
Lasers/Sources
Detectors/Imaging
Optics
Bio & Life Sciences
Laser Processing
Test/Measurement
Science & Research
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
BioOptics Stock Watch
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Cyclo Therapeutics, Inc.
< Previous
1
2
Next >
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
August 22, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
RFL
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
August 15, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer’s Disease from European Patent Office
July 29, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
June 25, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
May 30, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
RFL
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 16, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 18, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease
March 14, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer’s Disease from the U.S. Patent and Trademark Office
January 29, 2024
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
December 27, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
AMTI
CYTH
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
December 18, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
November 21, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
November 15, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
RFL
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million
October 23, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
October 05, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
September 21, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
AMTI
CYTH
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
August 15, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
RFL
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
August 02, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
RFL
Cyclo Therapeutics Announces Publication of Positive Data from Phase 2 Clinical Study of Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C1
June 29, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Allowance of Patent from European Patent Office for Trappsol® Cyclo™ for Alzheimer’s Disease
June 12, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement
June 05, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
RFL
Cyclo Therapeutics Provides Business Update and Reports First Quarter 2023 Financial Results
May 15, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
RFL
Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)
May 02, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
RFL
Cyclo Therapeutics Announces Closing of $1.3 Million Private Placement Priced At-The-Market Under Nasdaq Rules
April 21, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Provides Clinical Program Update and Highlights Recent Achievements
January 11, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
January 10, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces First Patient Dosed in Phase 2b Study of Trappsol® Cyclo™ for the Treatment of Early Alzheimer’s Disease
January 09, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Closing of $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
January 04, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces Abstract Accepted for Poster Presentation at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual Meeting
January 04, 2023
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
Cyclo Therapeutics Announces $4.2 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
December 30, 2022
From
Cyclo Therapeutics, Inc.
Via
Business Wire
Tickers
CYTH
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.